Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

In vivo CAR applications face a difficult trade-off between ultra-short LNP-mRNA expression and permanently integrating lentiviruses that carry oncogenic risks. Circular RNA provides a transient three-to-six-month expression window that is durable enough to clear solid and liquid tumors while remaining completely re-dosable and reversible.

Related Insights

The hype around in-vivo CAR-T overlooks that it's a more complex form of gene therapy. It relies on the same delivery vectors (AAVs, LNPs) that have caused patient deaths and off-target effects like liver concentration in simpler gene therapies, suggesting a difficult path to success.

Optimizing non-viral gene delivery requires screening across delivery systems, DNA payload conformations, and expression formats simultaneously. Switching from standard double-stranded DNA to single-stranded formats encoding circular RNA can generate immune-quiet vectors that exhibit high stability and prolonged in vivo expression without requiring viral capsids.

While redosing may be an option for RNA-based in vivo CAR-Ts, viral vector-based platforms face a significant challenge. The potential for an immune response against the vector, a well-known issue in AAV gene therapy, could prevent subsequent doses and limit the long-term treatment strategy for these therapies.

The in vivo CAR-T field is not a "winner-takes-all" market. A strategic split is emerging, reflected in Big Pharma M&A. Reversible, finite-exposure RNA-based therapies are preferred for autoimmune diseases due to safety, while more permanent lentiviral vectors are reserved for high-risk oncology indications.

The next frontier in cellular therapy is in-vivo CAR-T, where a gene for the CAR receptor is delivered into the patient (e.g., via mRNA lipid nanoparticles) to create CAR-T cells internally. This eliminates the complex and costly external manufacturing process, potentially creating an 'off-the-shelf' CAR-T therapy.

Despite exciting early efficacy data for in vivo CAR-T therapies, the modality's future hinges on the critical unanswered question of durability. How long the therapeutic effects last, for which there is little data, will ultimately determine its clinical viability and applications in cancer versus autoimmune diseases.

Current cell therapies like CAR-T involve permanent genetic modifications, a risk acceptable only for last-resort cases. By using transient RNAs that disappear after a few days, this new approach eliminates long-term genetic risk, making cell therapies safe enough to be considered for first-line treatment.

Create Medicines chose LNP-delivered RNA for its in vivo platform to give physicians control. Unlike permanent lentiviral approaches, repeatable dosing allows for adapting to tumor antigen escape and managing durability and safety over time. This flexibility is a core strategic advantage for complex diseases like solid tumors.

Unlike permanent gene-editing, the company's mRNA-based CAR-T therapy is transient, with T-cell programming lasting only 7-10 days. This temporary effect enhances safety by avoiding permanent genetic changes and provides crucial flexibility to repeat or adjust dosing to achieve desired durability, much like a traditional drug.

Beyond transient RNA, Create has developed a unique retrotransposon based on the human Line-1 element. This technology allows for stable, scarless gene delivery using only RNA, providing an option for durable expression (e.g., for CD19 CAR-T) alongside their transient approaches, creating a highly versatile platform.

Three-to-Six-Month In Vivo CAR Expression Balances Cancer Efficacy Against Permanent Vector Risks | RiffOn